logo
Discovery of α2-plasmin inhibitor and its congenital deficiency
Fibrinogen measurement to assess the risk of arterial thrombosis in individual patients
Fibrinogen measurement to assess the risk of arterial thrombosis in individual patients
When all else fails to stop massive bleeding from trauma
Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding
The quest for the Holy Grail of tissue factor pathway inhibitor deficiency has just begun
A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI)
Plasma von Willebrand factor levels and surrogates of atherosclerosis
Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects
Variability in response to aspirin
Two faces of high-molecular-weight kininogen (HK) in angiogenesis
Atorvastatin affects leukocyte gene expression in dyslipidemia patients
The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice
Clinical outcome of patients with venous thromboembolism and recent major bleeding
Thrombomodulin gene polymorphisms or haplotypes as potential risk factors for venous thromboembolism
Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis
Liver histology of an afibrinogenemic patient with the Bβ-L353R mutation showing no evidence of hepatic endoplasmic reticulum storage disease (ERSD); comparative study in COS-1 cells of the intracellular processing of the Bβ-L353R fibrinogen vs. the ERSD-associated γ-G284R mutant
Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses
Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count
Shiga toxin enhances functional tissue factor on human glomerular endothelial cells
SHPS-1 negatively regulates integrin αIIbβ3 function through CD47 without disturbing FAK phosphorylation
Provisional criteria for the diagnosis of VWD type 1
The use of LMWH in pregnancies at risk
The use of LMWH in pregnancies at risk
The use of LMWH in pregnancies at risk
The use of LMWH in pregnancies at risk
The use of LMWH in pregnancies at risk
The use of LMWH in pregnancies at risk
The use of LMWH in pregnancies at risk
The use of LMWH in pregnancies at risk
The use of LMWH in pregnancies at risk
The use of LMWH in pregnancies at risk
The use of LMWH in pregnancies at risk
Plasma von Willebrand factor and arterial aging
Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations
Evaluation of the von Willebrand factor Y1584C polymorphism as a potential risk factor for bleeding in patients receiving anticoagulant treatment with vitamin K antagonists
Inhibitor to factor VII in severe factor VII deficiency
Genetic variation in alcohol dehydrogenase 3 and the decrease of hs-C-reactive protein levels by moderate alcohol consumption
Factor VII gene polymorphisms are not associated with myocardial infarction in young women
Absence of Pro475Ser polymorphism in ADAMTS-13 in Caucasians
Functional analysis of two polymorphisms in the 3′-UTR of the human prothrombin gene
Novel missense mutations in two patients with factor XI deficiency (Val271Leu and Tyr351Ser) and one patient with combined factor XI and factor IX deficiency (Phe349Val)
Thrombophilia and venous thromboembolism after total hip or knee replacement surgery
More on
More on
Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology—a rebuttal
Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology—reply to a rebuttal
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity—a rebuttal
Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—reply to a rebuttal
Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—a rebuttal
Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—reply to a rebuttal
Platelets and Megakaryocytes – Functional Assays, Volume 1.
Platelets and Megakaryocytes – Perspectives and Techniques, Volume 2.
TALKING ABOUT…
ANNOUNCEMENTS
CORRIGENDUM